State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea.
ACS Nano. 2022 Sep 27;16(9):14029-14042. doi: 10.1021/acsnano.2c03858. Epub 2022 Aug 29.
During liver fibrogenesis, liver sinusoidal capillarization and extracellular matrix (ECM) deposition construct dual pathological barriers to drug delivery. Upon capillarization, the vanished fenestrae in liver sinusoidal endothelial cells (LSECs) significantly hinder substance exchange between blood and liver cells, while excessive ECM further hinders the delivery of nanocarriers to activated hepatic stellate cells (HSCs). Herein, an efficient nanodrug delivery system was constructed to sequentially break through the capillarized LSEC barrier and the deposited ECM barrier. For the first barrier, LSEC-targeting and fenestrae-repairing nanoparticles (named HA-NPs/SMV) were designed on the basis of the modification with hyaluronic acid and the loading of simvastatin (SMV). For the second barrier, collagenase I and vitamin A codecorated nanoparticles with collagen-ablating and HSC-targeting functions (named CV-NPs/siCol1α1) were prepared to deliver siCol1α1 with the goal of inhibiting collagen generation and HSC activation. Our results showed that upon encountering the capillarized LSEC barrier, HA-NPs/SMV rapidly released SMV and exerted a fenestrae-repairing function, which allowed more CV-NPs/siCol1α1 to enter the space of Disse to degrade deposited collagen and finally to achieve higher accumulation in activated HSCs. Scanning electronic microscopy images showed the recovery of liver sinusoids, and analysis of liver tissue sections demonstrated that HA-NPs/SMV and CV-NPs/siCol1α1 had a synergetic effect. Our pathological barrier-normalization strategy provides an antifibrotic therapeutic regimen.
在肝纤维化过程中,肝窦毛细血管化和细胞外基质(ECM)沉积构建了双重的药物传递病理屏障。在毛细血管化后,肝窦内皮细胞(LSEC)中消失的窗孔显著阻碍了血液和肝细胞之间的物质交换,而过多的 ECM 进一步阻碍了纳米载体向活化的肝星状细胞(HSCs)的传递。在此,构建了一种有效的纳米药物传递系统,以顺序突破毛细血管化的 LSEC 屏障和沉积的 ECM 屏障。对于第一个屏障,基于透明质酸修饰和辛伐他汀(SMV)装载,设计了 LSEC 靶向和窗孔修复纳米颗粒(命名为 HA-NPs/SMV)。对于第二个屏障,制备了具有胶原酶 I 和维生素 A 共载的具有胶原消融和 HSC 靶向功能的纳米颗粒(命名为 CV-NPs/siCol1α1),以递送 siCol1α1,目的是抑制胶原生成和 HSC 活化。我们的结果表明,遇到毛细血管化的 LSEC 屏障后,HA-NPs/SMV 迅速释放 SMV 并发挥窗孔修复功能,使更多的 CV-NPs/siCol1α1 进入 Disse 间隙降解沉积的胶原,最终在活化的 HSCs 中实现更高的积累。扫描电子显微镜图像显示肝窦恢复,肝组织切片分析表明 HA-NPs/SMV 和 CV-NPs/siCol1α1 具有协同作用。我们的病理屏障正常化策略提供了一种抗纤维化治疗方案。